"The U.S. Food and Drug Administration yesterday approved Rixubis [Coagulation Factor IX (Recombinant)] for use in people with hemophilia B who are 16 years of age and older. Rixubis is indicated for the control and prevention of bleeding episodes"...
Albumin is responsible for 70-80% of the colloid osmotic pressure of normal plasma, thus making it useful in regulating and increasing blood volume.4,5,6 It is also a transport protein and binds naturally occurring, therapeutic and toxic materials in the circulation.5,6 BUMINATE 5%, Albumin (Human), 5% Solution is osmotically equivalent to an equal volume of normal human plasma and will increase circulating plasma volume by an amount approximately equal to the volume infused. The degree and duration of volume expansion depends upon the initial blood volume. With patients treated for diminished blood volume, the effect of infused albumin may last for many hours. In patients with normal blood volumes, the hemodilution lasts for a shorter period.7,8
Total body albumin is estimated to be 350 g for a 70 kg man and is distributed throughout the extracellular compartments. The half-life of albumin is 15 to 20 days with a turnover of approximately 15 g per day.5
The minimum plasma albumin level necessary to prevent or reverse peripheral edema is unknown. Some investigators recommend that plasma albumin levels be maintained at approximately 2.5 g/dL. This concentration provides a plasma oncotic pressure value of 20 mm Hg.4
BUMINATE 5%, Albumin (Human), 5% Solution is manufactured by the modified Cohn-Oncley cold ethanol fractionation process which includes a series of cold-ethanol precipitation, centrifugation and/or filtration of human plasma followed by pasteurization of the final product at 60 ± 0.5°C for 10 - 11 hours. This process accomplishes both purification of albumin and the reduction of viruses.
In vitro studies demonstrate that the manufacturing process for BUMINATE 5%, Albumin (Human), 5% Solution provides for significant viral reduction. These viral reduction studies, summarized in Table 1, demonstrate viral clearance during the manufacturing process for BUMINATE 5%, Albumin (Human), 5% Solution using human immunodeficiency virus, type 1 (HlV-1) both as a relevant and model virus for HIV-2 and other enveloped RNA viruses; bovine viral diarrheal virus (BVD), a model for lipid enveloped RNA viruses, such as hepatitis C virus (HCV); porcine parvovirus (PPV), a model for non-lipid enveloped DNA viruses such as human parvovirus B19; hepatitis A virus (HAV), a relevant virus and a model for non-lipid enveloped RNA viruses.
These studies indicate that specific manufacturing steps for BUMINATE 5%, Albumin (Human), 5% Solution are capable of eliminating/inactivating a wide range of relevant and model viruses. Since the mechanism of virus elimination/inactivation at each step is different, the overall manufacturing process of BUMINATE 5%, Albumin (Human), 5% Solution is robust in reducing viral load.
|Summary of Viral Reduction Factor for Each Virus and Processing Step|
|Process Step||Viral Reduction Factor (log10)|
|Lipid Enveloped||Non-lipid Enveloped|
|Step 1: Processing of cryo-poor plasma to Fraction I+II+III centrifugate||1.2±0.0||5.8±0.0||4.6±0.5||1.9±0.8||1.4±0.1|
|Step 2: Processing of Fraction I+II+III centrifugate to Fraction IV1 centrifugate||2.8±0.5||NCM||3.4±0.4||1.9±0.7||(1.2±0.3)*|
|Step 3: Processing of Fraction IV1 centrifugate to Fraction IV4 centrifugate/ filter press filtrate†|| > 2.4±0.1/
| > 4.4±0.5/
| > 4.8±0.1/
|3.8±0.1/ 2.9±0.2||2.2±0.3/ 2.0±0.3|
|Step 4: Processing of Fraction IV4 centrifugate/ filter press filtrate to Fraction IV4 Cuno 70C filtrate††|| > 1.6±0.2/
|NCM|| > 4.1±0.5/
|4.7±0.1/ 4.6±0.1||2.3±0.3/ 3.0±0.8|
|Step 5: Processing of Fraction V suspension to Cuno 90LP filtrate||(0.2±0.2)*||> 5.0±0.5||> 4.6±0.0||4.2±0.4||3.4±0.5|
|Step 6: Pasteurization||> 4.9±0.1||> 5.1±0.3||> 5.3±0.1||5.3±0.4||NT|
|Cumulative Reduction Factor**, log10||>12.9/13.0||> 20.3/20.4||> 26.8/27.1||21.8/20.8||9.3/9.8|
|NT Not tested.
NCM No virus reduction claim made at this step.
* Since the reduction factor of < 1.0 is within the variability limit of the assay, these values are not included in the computation of the cumulative reduction factor.
† Two reduction factors indicate the two liquid-solid separation options available at this step.
†† Two reduction factors indicate the two starting materials at this step.
** Two cumulative reduction factors derived from the use of the two liquid-solid separation options available at Step 3.
4. Tullis JL: Albumin, 1. Background and use, and 2. Guidelines for clinical use. JAMA 237:355-360,460-463, 1977
5. Peters T Jr: Serum albumin, in The Plasma Proteins, 2nd ed, Vol 1. Putnam FW (ed). New York, Academic Press, 1975, pp 133-181
6. Finlayson JS: Albumin products. Sem Thromb Hemostas 6:85-120, 1980
7. Janeway CA: Berenberg W, Hutchins G: Indications and uses of blood, blood derivatives and blood substitutes. Med Clin N Amer 29:10691094, 1945
8. Janeway CA, Gibson ST, Woodruff LM, et al: Chemical, clinical and immunological studies on the products of human plasma fractionation. VII. Concentrated human serum albumin. J Clin Invest 23:465-490, 1944
Last reviewed on RxList: 1/21/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Buminate 5% Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.